Merck & Co., Inc. Sales Revenue, Goods, Net (Deprecated 2018-01-31)
Merck & Co., Inc. (MRK) reported Sales Revenue, Goods, Net (Deprecated 2018-01-31) of $10.04 billion for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-08.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SalesRevenueGoodsNet · last filed 2018-05-08
- Merck & Co., Inc. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $10.04B, a 6.39% increase year-over-year.
- Merck & Co., Inc. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $10.43B, a 3.14% increase year-over-year.
- Merck & Co., Inc. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $10.32B, a 2.00% decline year-over-year.
- Merck & Co., Inc. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $9.93B, a 0.87% increase year-over-year.
- Merck & Co., Inc. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2017 was $40.12B, a 0.79% increase from fiscal 2016.
- Merck & Co., Inc. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2016 was $39.81B, a 0.78% increase from fiscal 2015.
- Merck & Co., Inc. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2015 was $39.50B, a 6.48% decline from fiscal 2014.
- Merck & Co., Inc. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2014 was $42.24B, a 4.08% decline from fiscal 2013.
| Period end | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 3 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 6 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 9 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-03-31 | $10.04B 10-Q · filed 2018-05-08 | $20.47B derived: sum of 2 quarters · filed 2018-05-08 | $30.80B derived: sum of 3 quarters · filed 2018-05-08 | $40.73B derived: sum of 4 quarters · filed 2018-05-08 |
| 2017-12-31 | $10.43B derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $20.76B derived: sum of 2 quarters · filed 2018-02-27 | $30.69B derived: sum of 3 quarters · filed 2018-02-27 | $40.12B 10-K · filed 2018-02-27 |
| 2017-09-30 | $10.32B 10-Q · filed 2017-11-07 | $20.25B derived: sum of 2 quarters · filed 2017-11-07 | $29.69B 10-Q · filed 2017-11-07 | $39.80B derived: sum of 4 quarters · filed 2018-05-08 |
| 2017-06-30 | $9.93B 10-Q · filed 2017-08-08 | $19.36B 10-Q · filed 2017-08-08 | $29.48B derived: sum of 3 quarters · filed 2018-05-08 | $40.02B derived: sum of 4 quarters · filed 2018-05-08 |
| 2017-03-31 | $9.43B 10-Q · filed 2018-05-08 | $19.55B derived: sum of 2 quarters · filed 2018-05-08 | $30.09B derived: sum of 3 quarters · filed 2018-05-08 | $39.93B derived: sum of 4 quarters · filed 2018-05-08 |
| 2016-12-31 | $10.12B derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $20.65B derived: sum of 2 quarters · filed 2018-02-27 | $30.50B derived: sum of 3 quarters · filed 2018-02-27 | $39.81B 10-K · filed 2018-02-27 |
| 2016-09-30 | $10.54B 10-Q · filed 2017-11-07 | $20.38B derived: sum of 2 quarters · filed 2017-11-07 | $29.69B 10-Q · filed 2017-11-07 | $39.91B derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-06-30 | $9.84B 10-Q · filed 2017-08-08 | $19.16B 10-Q · filed 2017-08-08 | $29.37B derived: sum of 3 quarters · filed 2018-02-27 | $39.44B derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-03-31 | $9.31B 10-Q · filed 2017-05-09 | $19.53B derived: sum of 2 quarters · filed 2018-02-27 | $29.60B derived: sum of 3 quarters · filed 2018-02-27 | $39.38B derived: sum of 4 quarters · filed 2018-02-27 |
| 2015-12-31 | $10.21B derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $20.29B derived: sum of 2 quarters · filed 2018-02-27 | $30.07B derived: sum of 3 quarters · filed 2018-02-27 | $39.50B 10-K · filed 2018-02-27 |
| 2015-09-30 | $10.07B 10-Q · filed 2016-11-07 | $19.86B derived: sum of 2 quarters · filed 2016-11-07 | $29.28B 10-Q · filed 2016-11-07 | $39.77B derived: sum of 4 quarters · filed 2017-02-28 |
| 2015-06-30 | $9.79B 10-Q · filed 2016-08-08 | $19.21B 10-Q · filed 2016-08-08 | $29.69B derived: sum of 3 quarters · filed 2017-02-28 | $40.25B derived: sum of 4 quarters · filed 2017-02-28 |
| 2015-03-31 | $9.43B 10-Q · filed 2016-05-09 | $19.91B derived: sum of 2 quarters · filed 2017-02-28 | $30.46B derived: sum of 3 quarters · filed 2017-02-28 | $41.40B derived: sum of 4 quarters · filed 2017-02-28 |
| 2014-12-31 | $10.48B derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $21.04B derived: sum of 2 quarters · filed 2017-02-28 | $31.97B derived: sum of 3 quarters · filed 2017-02-28 | $42.24B 10-K · filed 2017-02-28 |
| 2014-09-30 | $10.56B 10-Q · filed 2015-11-05 | $21.49B derived: sum of 2 quarters · filed 2015-11-05 | $31.75B 10-Q · filed 2015-11-05 | $43.08B derived: sum of 4 quarters · filed 2016-02-26 |
| 2014-06-30 | $10.93B 10-Q · filed 2015-08-06 | $21.20B 10-Q · filed 2015-08-06 | $32.52B derived: sum of 3 quarters · filed 2016-02-26 | $43.55B derived: sum of 4 quarters · filed 2016-02-26 |
| 2014-03-31 | $10.26B 10-Q · filed 2015-05-07 | $21.58B derived: sum of 2 quarters · filed 2016-02-26 | $32.62B derived: sum of 3 quarters · filed 2016-02-26 | $43.63B derived: sum of 4 quarters · filed 2016-02-26 |
| 2013-12-31 | $11.32B derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26 | $22.35B derived: sum of 2 quarters · filed 2016-02-26 | $33.36B derived: sum of 3 quarters · filed 2016-02-26 | $44.03B 10-K · filed 2016-02-26 |
| 2013-09-30 | $11.03B 10-Q · filed 2014-11-10 | $22.04B derived: sum of 2 quarters · filed 2014-11-10 | $32.71B 10-Q · filed 2014-11-10 | $44.45B derived: sum of 4 quarters · filed 2015-02-27 |
| 2013-06-30 | $11.01B 10-Q · filed 2014-08-07 | $21.68B 10-Q · filed 2014-08-07 | $33.42B derived: sum of 3 quarters · filed 2015-02-27 | $44.91B derived: sum of 4 quarters · filed 2015-02-27 |
| 2013-03-31 | $10.67B 10-Q · filed 2014-05-08 | $22.41B derived: sum of 2 quarters · filed 2015-02-27 | $33.90B derived: sum of 3 quarters · filed 2015-02-27 | $46.21B derived: sum of 4 quarters · filed 2015-02-27 |
| 2012-12-31 | $11.74B derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27 | $23.23B derived: sum of 2 quarters · filed 2015-02-27 | $35.54B derived: sum of 3 quarters · filed 2015-02-27 | $47.27B 10-K · filed 2015-02-27 |
| 2012-09-30 | $11.49B 10-Q · filed 2013-11-07 | $23.80B derived: sum of 2 quarters · filed 2013-11-07 | $35.53B 10-Q · filed 2013-11-07 | $47.82B derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-06-30 | $12.31B 10-Q · filed 2013-08-07 | $24.04B 10-Q · filed 2013-08-07 | $36.34B derived: sum of 3 quarters · filed 2014-02-27 | $48.36B derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-03-31 | $11.73B 10-Q · filed 2013-05-09 | $24.02B derived: sum of 2 quarters · filed 2014-02-27 | $36.05B derived: sum of 3 quarters · filed 2014-02-27 | $48.20B derived: sum of 4 quarters · filed 2014-02-27 |
| 2011-12-31 | $12.29B derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-27 | $24.32B derived: sum of 2 quarters · filed 2014-02-27 | $36.47B derived: sum of 3 quarters · filed 2014-02-27 | $48.05B 10-K · filed 2014-02-27 |
| 2011-09-30 | $12.02B 10-Q · filed 2012-11-09 | $24.17B derived: sum of 2 quarters · filed 2012-11-09 | $35.75B 10-Q · filed 2012-11-09 | $47.85B derived: sum of 4 quarters · filed 2013-02-28 |
| 2011-06-30 | $12.15B 10-Q · filed 2012-08-07 | $23.73B 10-Q · filed 2012-08-07 | $35.83B derived: sum of 3 quarters · filed 2013-02-28 | $46.95B derived: sum of 4 quarters · filed 2013-02-28 |
| 2011-03-31 | $11.58B 10-Q · filed 2012-05-08 | $23.67B derived: sum of 2 quarters · filed 2013-02-28 | $34.80B derived: sum of 3 quarters · filed 2013-02-28 | $46.15B derived: sum of 4 quarters · filed 2013-02-28 |
| 2010-12-31 | $12.09B derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-28 | $23.22B derived: sum of 2 quarters · filed 2013-02-28 | $34.56B derived: sum of 3 quarters · filed 2013-02-28 | $45.99B 10-K · filed 2013-02-28 |
| 2010-09-30 | $11.13B 10-Q · filed 2011-11-08 | $22.47B derived: sum of 2 quarters · filed 2011-11-08 | $33.89B 10-Q · filed 2011-11-08 | |
| 2010-06-30 | $11.35B 10-Q · filed 2011-08-08 | $22.77B 10-Q · filed 2011-08-08 | ||
| 2009-12-31 | $27.43B 10-K · filed 2012-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |